Hosted on MSN5d
EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drugBRUSSELS (AP) — The European Commission said Thursday it has fined Israeli generic drugmaker Teva more than 460 million euros ...
Teva Pharmaceuticals is being fined $503 million (€463 million) by the European Commission for delaying competition posed by ...
European Commission says company abused ‘dominant position’ to ‘artificially’ extend patent protection of MS medicine ...
The fine of €462.6 million ($503 million) is believed to be the largest imposed on a pharma company for breaking antitrust ...
Some two years after the European Commission accused Teva of meddling with the competition for its former multiple sclerosis blockbuster Copaxone, the other shoe has finally dropped. | The European ...
Teva Statement on European Commission Decision; Company to Appeal GlobeNewswire October 31, 2024 Teva Pharmaceuticals ...
The European Commission (EC) has fined pharmaceutical company Teva €462.6 million for “systematically spread[ing] misleading ...
The European Commission announced Thursday it had imposed an antitrust fine exceeding 460 million euros ($500 million) on ...
Teva Pharmaceutical Industries Ltd. has been fined nearly €463 million ($503 million) by the European Union’s antitrust ...
Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns ...
The European Commission has fined Israeli drugmaker Teva Pharmaceutical Industries (NYSE:TEVA) EUR 462.6M, or around $500M, for trying to ward off competition for its blockbuster multiple sclerosis ...
The European Commission has fined Teva Pharmaceuticals €462.6m for abusing its dominant market position by blocking ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback